MICROTUBULE TARGETING AGENTS
Provided are methods for treating cancers responsive to the modulation of microtubule assembly and P-gp-mediated resistant cancers using 2-(difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1H-1,2,4-triazol-3-yl]methyl]benzamide, or a pharmaceutically acceptable salt thereof.
1 . A method of treating a cancer responsive to the modulation of microtubule assembly comprising administering to a subject in need thereof, a therapeutically effective amount of 2-(difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1H-1,2,4-triazol-3-yl]methyl]benzamide, or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the cancer is selected from prostate cancer, head and neck cancer, endometrial cancer, glioblastoma multiforme, sarcoma, and lung cancer.
3 . The method of claim 1 , wherein the cancer is prostate cancer.
4 . The method of claim 1 , wherein the cancer is head and neck cancer.
5 . The method of claim 1 , wherein the cancer is lung cancer.
6 . The method of claim 5 , wherein the lung cancer is small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC).
7 . The method of claim 1 , wherein the cancer is endometrial cancer.
8 . The method of claim 1 , wherein the cancer is glioblastoma multiforme.
9 . The method of claim 1 , wherein the cancer is sarcoma.
10 . A method of treating a P-gp-mediated resistant cancer comprising administering to a subject in need thereof, a therapeutically effective amount of 2-(difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1H-1,2,4-triazol-3-yl]methyl]benzamide, or a pharmaceutically acceptable salt thereof.
11 . The method of claim 10 , wherein the cancer is a taxane resistant cancer.
12 . The method of claim 10 , wherein the cancer is resistant to paclitaxel, vinblastine, vincristine, or docetaxel.
13 . The method of claim 10 , wherein the cancer is resistant to paclitaxel.
14 . The method of claim 10 , wherein the cancer is selected from ovarian, prostate, breast, bladder, head and neck, and lung cancer.
15 . The method of claim 10 , wherein the cancer is ovarian cancer.
16 . The method of claim 10 , wherein the cancer is breast cancer.
17 . The method of claim 10 , wherein the cancer is bladder cancer.
18 . The method of claim 10 , wherein the cancer is head and neck cancer.
19 . The method of claim 10 , wherein the cancer is lung cancer.
20 . The method of claim 10 , wherein the cancer is a vinca alkaloid resistant cancer.
21 . The method of claim 10 , wherein the cancer is resistant to vinblastine or vincristine.
22 . The method of claim 10 , wherein the cancer is selected from lymphoma, acute lymphocytic leukemia (ALL), and solid tumors.